New combo therapy aims to shrink untreatable liver tumors
NCT ID NCT07180459
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tests a new approach for people with liver cancer that cannot be removed by surgery. Doctors will use tiny drug-coated beads to block blood flow to the tumor (a procedure called TACE) along with a targeted pill called Donafenib. The goal is to see if this combination can shrink tumors and help patients live longer. About 118 participants will be enrolled, and the study will track how long the cancer stays under control.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Donafenib (a targeted cancer drug) and drug-loaded microspheres (tiny beads that deliver chemotherapy directly to the tumor)
What this could lead to
If it works, this could offer a more effective way to control liver cancer that cannot be removed by surgery, potentially extending life and delaying tumor growth.
What could go wrong
This is an early, single-arm observational study with no comparison group, so results may not be definitive. The combination therapy also carries risks like liver damage, bleeding, or side effects from the drugs.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Deng zhou People's Hospital
Nanyang, Henan, China
-
First People's Hospital of Shangqiu
Shangqiu, Henan, China
-
Huai He Hospital of Henan University
Kaifeng, Henan, China
-
Jiangxi Provincial People's Hospitail
Nanchang, Jiangxi, China
-
Luo He Central Hospital
Luohe, Henan, China
-
Luo Yang Central Hospital
Luoyang, Henan, China
-
People's Hospital of Kaiyang County
Guiyang, Guizhou, China
-
Second People's Hospital of Jiaozuo
Jiaozuo, China
-
The Second Affiliated Hospital of Hainan Medical Universsity
Haikou, Hainan, China
-
Zhou Kou Central Hospital
Zhoukou, Henan, China